Product Pipeline
The BioLineRx pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies or which address unmet medical needs.
Over 2,000 compounds have already been systematically screened and evaluated, of which over forty commenced development.
Today 15 compounds are actively being developed, including six in clinical stages.
For a printable version of the pipeline in pdf format, please click on the link below:
BioLineRx Pipeline Graph
BioLineRx Pipeline Graph
BL-1020 Schizophrenia (Currently in Phase II/III trial) |
 |
|
BL-1040 AMI (Currently in CE Mark Registration Trial) |
|
|
BL-5010 Skin lesions (Phase I/II complete) |
|
|
BL-7040 Inflammatory Bowel Disease ( Phase II) |
|
|
BL-8040 Acute myeloid leukemia & other hematological cancers (Phase II ready) |
|
|
BL-1021 Neuropathic Pain (Currently in Phase I trial) |
|
|
BL-8020 Hepatitis C (HCV) |
|
|
BL-7010 Celiac Disease |
|
|
BL-5040 Cachexia (BIJ) |
|
|
BL-7060/EDP29 Inflammatory diseases |
|
|
BL-8030 Hepatitis C (HCV) |
|
|
BL-9010 Severe allergies/asthma |
|
|
